肝胆相照论坛

标题: EASL2019:FXR激动剂或可抑制cccDNA形成及病毒mRNA转录 [打印本页]

作者: newchinabok    时间: 2019-4-19 08:17     标题: EASL2019:FXR激动剂或可抑制cccDNA形成及病毒mRNA转录

本帖最后由 newchinabok 于 2019-4-19 08:18 编辑

EASL2019:FXR激动剂或可抑制cccDNA形成及病毒mRNA转录
2019-04-18来源:一诺医学作者:略晓薛

HBV感染和胆汁酸代谢是相互依存的。 HBV感染增加感染患者中BA核受体FXR的表达。 相反,FXR是HBV的前病毒因子,其活性在体外和体内被FXR激动剂抑制。FXR的存在有利于cccDNA完成以及病毒mRNA转录,可能是通过其与两个HBV基因组位点(FXRE)的结合完成。

由于FXR和HBx相互作用,破译HBx和FXR以及配体在控制HBV转录中的各自作用成为法国研究人员 Benoît Lacombe 等人的研究目标。

在HBV允许分化的HepaRG(dHepaRG)和肝癌细胞系Huh7中研究FXR的表达。用 HBV WT 或 ΔHBx-HBV 感染 dHepaRG 。 在含有两个 FXRE 的 HBV Enh2 / Cp 调节区转染的 Huh7 中实现 ChIP。

通过FXR shRNA产生FXR KO Huh7细胞系以研究HBx对FXRE FXR固定的影响。 FXR激动剂 GW4064(GW)的使用剂量级为 10μM 。

当用 FXR 激动剂治疗降低该表达时,野生型或 ΔHBx-HBV 的HBV感染在蛋白水平上增加FXR表达,与体内研究观察一致。

通过激动剂对FXR的下调使得该分子对dHepaRG中FXR与FXRE结合的影响难以研究。

相反,激动剂增加了Huh7中的FXR蛋白表达和/或稳定化。

因此,研究人员利用这种特殊的FXR表达调控在Enh2 / Cp启动子转染的Huh7中进行 FXR 和 HBx-ChIP。FXR-ChIP 以剂量依赖性方式显示Enh2 / cp中FXR的存在。

与BSEP启动子的FXR稳定化相比,GW 处理降低了FXR在病毒启动子处的存在。

RXR 也在Enh2 / Cp中聚集并在GW处理后释放,再次与BSEP启动子的稳定性不一致。

当HBx在具有Enh2 / Cp区域的Huh7或shFXR-Huh7细胞中共转染时,HBx被聚集到病毒启动子中但不在shFXR-Huh7细胞中或在激动剂存在下。

总之,研究数据表明FXR前病毒活性依赖于其与Enh2 / Cp区域的病毒基因组的结合。

FXR 的存在可能会助力cccDNA形成的细胞因子聚集和HBx用于有效转录。

激动剂对FXR前病毒活性的抑制可能是由于FXR表达的抑制和FXR从其病毒靶标的释放引起的。 后作用效应似乎是DNA序列依赖性的,因为激动剂稳定细胞启动子上的FXR。
作者: StephenW    时间: 2019-4-19 11:05

SAT-175
Recruitment of HBx on HBV DNA depends on FXR and is inhibited
by FXR agonist
Benoît Lacombe1, Camille Ménard1, Vincent Lotteau1, Patrice Andre1,
Christophe Ramière1. 1INSERM U1111-CNRS UMR5308-Université Lyon
1 and ENS de Lyon, CIRI, Lyon, France
Email: [email protected]
Background and aims: HBV infection and bile acids metabolism are
interdependent. HBV infection increases expression of the BA nuclear
receptor FXR in infected patients. Reciprocally, FXR is a proviral factor
for HBV whose activity is inhibited by FXR agonists, in vitro and in
vivo. Presence of FXR favors cccDNA completion as well as viral
mRNAs transcription, likely through its binding to two HBV genome
sites (FXRE). Since FXR and HBx interact,we aimed at deciphering the
respective role of HBx and FXR, and ligand, in controlling HBV
transcription.
Method: Expression of FXR was studied in HBV-permissive differentiated
HepaRG (dHepaRG) and in hepatocarcinoma cell line Huh7.
dHepaRG were infected HBVWT or ΔHBx-HBV. ChIP were realized in
Huh7 transfected with Enh2/Cp regulatory region of HBV containing
the two FXRE. FXR KO Huh7 cell line was generated through FXRshRNA
to study the impact of HBx on FXR fixation at FXRE. FXR
agonist GW4064 (GW) was used at 10μM.
Results: HBV infection with either wild type or ΔHBx-HBV increased
FXR expression at the protein level in agreement with in vivo
observations, when treatment with FXR agonist decreased this
expression. Down regulation of FXR by agonists renders difficult
studying the effect of that molecule on FXR binding to FXRE in
dHepaRG. On the opposite, agonist increased FXR protein expression
and/or stabilization in Huh7. We thus took advantage of this
particular FXR expression regulation to perform FXR and HBx-ChIP
in Huh7 transfected with Enh2/Cp promoter. FXR-ChIP revealed FXR
presence in the Enh2/cp in a dose dependent manner. GWtreatment
decreased FXR presence at the viral promoter in contrast to FXR
stabilization at the BSEP promoter. RXR was also recruited at the
Enh2/Cp and released after GW treatment, again at odds with the
stabilization at the BSEP promoter. When HBx was cotransfected in
Huh7 or shFXR-Huh7 cells with Enh2/Cp region, HBxwas recruited to
the viral promoter but not in the shFXR-Huh7 cells or in presence of
agonist.
Conclusion: Altogether, data suggest that FXR proviral activity
depends on its binding to the viral genome at the Enh2/Cp region.
Presence of FXR might recruit cellular factors for cccDNA completion
and HBx for efficient transcription. Inhibition of FXR proviral activity
by agonist might result from repression of FXR expression and of the
release of FXR from its viral targets. This later effect seems to be DNA
sequence dependent since agonist stabilize FXR on cellular promoter.
作者: fuke    时间: 2019-4-19 11:49

理论都是好的,进去临床就不行了
作者: newchinabok    时间: 2019-4-19 13:59

更新




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5